FDA Launches Safety Review of Mifepristone Under Trump Administration
FDA launches safety review of mifepristone, approved since 2000 and used in majority of U.S. abortions.
Event / Politics
Mifepristone Abortion Pill Legal Battle
Ongoing legal disputes over access to mifepristone, including Supreme Court stays and lower court rulings affecting FDA regulations on mail-order distribution and remote prescription of the medication.
3 reported locations
Daily activity
0 articles0 articles
2026-08-17 to 2026-11-14 · UTC publication dates
Coverage begins 2 May, 00:37 UTC
Follow the documented timeline or explore the related reporting.
What happened
5th Circuit Court of Appeals blocks mailing of mifepristone abortion pill
The 5th U.S. Circuit Court of Appeals issued a ruling requiring that mifepristone, an abortion pill, be distributed only in-person at clinics. The decision blocks the FDA allowance that had permitted prescriptions to be mailed to patients. The court ruling stated that every abortion facilitated by the FDA's action cancels Louisiana's ban on medical abortions.
FDA relaxed mifepristone distribution restrictions during COVID-19 pandemic
During the COVID-19 pandemic years, the FDA under President Joe Biden dropped restrictions on mifepristone prescription and distribution. After more than 20 years of monitoring mifepristone use and reviewing dozens of studies involving thousands of women, FDA officials determined that women could safely use the pill without direct medical supervision.
Louisiana attorney general seeks rollback of FDA mifepristone regulations
Louisiana's attorney general and a woman claiming she was coerced into taking abortion pills requested that FDA rules be rolled back to previous restrictions requiring mifepristone to be prescribed and dispensed only in person at clinics.
Supreme Court unanimously preserved access to mifepristone in 2024
The Supreme Court unanimously preserved access to mifepristone in a 2024 decision. However, the ruling sidestepped core issues by determining that anti-abortion doctors who brought the case did not have legal standing to sue.
FDA approved mifepristone in 2000 as safe abortion method
The FDA approved mifepristone in 2000 as a safe and effective way to end early pregnancies. Mifepristone is typically used in combination with a second drug, misoprostol. Initially, the FDA imposed strict limits on prescription and distribution due to rare cases of excessive bleeding.
Supreme Court previously overturned Roe v. Wade in 2022
The Supreme Court issued a 2022 ruling that overturned Roe v. Wade, eliminating abortion as a nationwide constitutional right and allowing states to enforce abortion bans. This decision enabled individual states to restrict or ban abortion access.
FDA under Trump administration conducting new safety review of mifepristone
FDA officials under President Donald Trump stated the agency is conducting a new review of mifepristone's safety at the direction of the president. In court filings, the FDA could not specify when the review might be complete and acknowledged it was still collecting data.
Read the coverage
2 alternative perspectives
Appeals court temporarily suspends telemedicine mifepristone access nationwide
Appeals court suspends telemedicine mifepristone access; Supreme Court to decide on extending restrictions.
Democratic states pass laws protecting abortion pill prescribers
Democratic states enact protective laws for abortion pill prescribers amid federal restrictions.
Supreme Court precedent anchors mifepristone's FDA approval despite ongoing restrictions
FDA approval from 2000 remains the baseline precedent constraining lower court restrictions on mifepristone.
Supreme Court blocks Fifth Circuit restrictions on mifepristone access
Supreme Court blocks lower court restrictions on mifepristone mail delivery and telehealth access.
Mifepristone: FDA approval, usage patterns, and regulatory foundations
FDA approved mifepristone in 2000; it now represents the majority method for abortion in America.
Louisiana challenges FDA's telehealth mifepristone rule in court
Louisiana sues to overturn FDA's 2023 telehealth mifepristone distribution rule.
Mifepristone manufacturers escalate legal challenges to Fifth Circuit restrictions
Two mifepristone manufacturers are appealing the Fifth Circuit's block on mail and telehealth distribution to higher courts.
Medication abortions surge to 60 percent as access restrictions tighten
Medication abortions now dominate U.S. abortion practice, yet court restrictions are blocking primary access pathways.
Mifepristone manufacturer escalates legal fight with Supreme Court emergency appeal
Mifepristone manufacturer escalates legal fight with emergency Supreme Court appeal against mailing restrictions.
Four-year legal battle over mifepristone traces shifting judicial landscape
Four years of legal battles show shifting judicial treatment of mifepristone access despite Supreme Court precedent.
Trump administration intensifies mifepristone enforcement through cabinet appointments
Trump administration shifts mifepristone enforcement through cabinet appointments and new safety reviews.